Copy
In this issue...News on Quebec multi-centre trial, German Breast Group trial and Canine study, Professional conferences and more…
 

Newsletter

Spring 2015

RDA™Trial in Quebec, Canada completed


The Tumour RDA pilot study in Quebec, led by Dr. Jean-Francois Boileau of Montreal Jewish General Hospital, has been completed.

The two most important findings confirmed by the trial are RNA disruption can be detected as early as following the first cycle of chemotherapy treatment and the test can be performed with fine needle aspiration (FNA) biopsies versus core biopsies. FNAs can be performed in a doctor’s office making it easier for patients and more efficient.

"We are very pleased we met objectives for the pilot study by confirming optimal timing for the biopsy and the feasibility of FNA biopsies," said Dr. Boileau. "RDA is a very promising assay with potential to tailor the treatment for breast cancer patients around the world." Dr. Boileau will present the results of this research at a meeting of breast cancer researchers in Toronto in May. Dr. Boileau is a surgical oncologist and clinician scientist at the Montreal Jewish General Hospital. He is an assistant professor in the Department of Surgery at McGill University.

“We continue to build the evidence required by clinicians to utilize RDA in breast cancer chemotherapy treatment. RDA provides information to clinicians critical to treatment decisions,” said Dr. Ken Pritzker, President and CEO of Rna Diagnostics.
 

German Breast Group Clinical Trial


The German Breast Group (GBG) has approved the protocol for the “RNA Disruption Assay: Tumour Response Guide for Response Guided Breast Cancer Therapy" clinical trial to be conducted at the Luisenkrankenhaus hospital in Düsseldorf. Clinical Advisory Board member and Managing Director of GBG,  Gunter von Minckwitz, is the Principle Investigator for the trial which will study RDA in 200 patients treated with neoadjuvant chemotherapy.

University of Guelph Canine study completed

A study of canine lymphoma utilizing RDA, in partnership with the University of Guelph Institute for Comparative Cancer Investigation and the Ontario Veterinary College has been completed and the data has been analyzed. Next steps include following the dogs in the study to determine outcomes.

"This sort of collaborative trial that uses naturally occurring cancer in dogs as a translational model for human oncology is one of the main aims of the ICCI. We are excited by the opportunity this study presents to improve our understanding of canine lymphoma responses to chemotherapy, and we look forward to analyzing the final outcome data with our colleagues at Rna Diagnostics," said Dr. Brenda Coomber of the OVC.
 
Lymphoma is one of the most prevalent cancers for dogs, and is frequently treated with combination chemotherapy. While standard of care CHOP protocol is highly effective at inducing initial remission in most dogs, approximately 60% of treated dogs will either fail to achieve initial remission, or will relapse within 6 months. Second line 'rescue' therapy can be successful, but at this time there is no way of identifying which dogs should abandon CHOP and switch to rescue regimes, other than waiting for them to fail to achieve remission or to relapse early.

Future clinical trials may explore how best to use this biomarker to choose optimal treatment for all dogs with lymphoma. It is also possible that RDA analysis will be informative for treatment outcome in other types of companion animal cancer. The Animal Cancer Centre at OVC treats hundreds of canine cancer patients annually.


Rna Diagnostics Connects with Clinicians

SABCS 2014
Rna Diagnostics attended the San Antonio Breast Cancer Symposium (SABCS) this year, meeting with over two dozen breast oncologists from leading research institutions around the world. Rna Diagnostics received strong, positive interest in RDA and is pursuing collaboration opportunities with clinical oncology groups in North America, Europe and Asia.
 
SABCS provides state-of-the-art information on breast cancer research attended by a broad international audience of academic and private researchers and physicians from over 90 countries. This international symposium is directed primarily towards academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as other appropriate health care professionals.

Dr. Jean-Francois Boileau

ICYMI – Rna Diagnostics was featured online, in print and on TV,  as well as being active in the global cancer community via social media in the past few months. Below are the links for your reference.

Better World Project
Laurentian Alumni newsletter
CTV North coverage

Feb 4, 2015 was World Cancer Day, an awareness campaign featuring global events and social media. World Cancer Day featured the hashtags #NotBeyondUs and #WorldCancerDay and was trending for most of the day.
Follow us on twitter @rnadiagnostics


Management Team

Ken Pritzker, MD, FRCPC
President & CEO

Amadeo Parissenti, PhD
Chief Scientific Officer

John Connolly, MBA
VP Corporate Development

John Jordan, MBA, CPA, CMA
Chief Financial Officer

Laura Pritzker, PhD
Principal Scientist

Clinical Advisory Board

Maureen E. Trudeau, MA, MD, FRCPC, Toronto, Canada

Gunter von Minckwitz, MD, PhD, Frankfurt, Germany

Michael Untch, MD, PhD, Berlin, Germany

Harry D. Bear, MD, PhD, Richmond, VA, USA

Professional Events

LABCNC 2015

Rna Diagnostics will be attending the Local Advanced Breast Cancer National Consensus in Cambridge, Ontario, Canada on May 3-4, 2015. Dr. Amadeo Parissenti, Rna Diagnostics, will present RDA preclinical data at the Cambridge meeting.

St. Gallen-Breast Cancer  Conference

Rna Diagnostics attended the 14th St. Gallen-Breast Cancer Conference in Vienna, Austria on March 18-21, 2015.
This conference features worldwide breast cancer experts presenting their latest data, critically reviewed by leading specialists in the field. Participants will be clinical oncologists, surgeons, gynaecologists, pathologists, epidemiologists, breast cancer nurses and scientists from all over the world. The conference closes with the widely acknowledged St. Gallen consensus on the optimal treatment of early breast cancer for the next two years.

 

Rna Diagnostics Inc. is a Canadian molecular diagnostics company developing diagnostic tools to improve chemotherapy management. rnadiagnostics.com

Our mailing address is:
Rna Diagnostics Inc.
MaRS Centre, Heritage Building, 101 College Street, Suite HL20-4, Toronto, ON, Canada
Toronto, ON M5G 1L7
Canada

Add us to your address book
For more information contact:
John Connolly
VP Corporate Development
416-985-4361
jconnolly@rnadiagnostics.com